View Financial HealthLonza Group 배당 및 자사주 매입배당 기준 점검 3/6Lonza Group 수익으로 충분히 충당되는 현재 수익률 1.02% 보유한 배당금 지급 회사입니다.핵심 정보1.0%배당 수익률1.5%자사주 매입 수익률총 주주 수익률2.5%미래 배당 수익률1.4%배당 성장률5.4%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향39%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • May 05Upcoming dividend of CHF5.00 per shareEligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (0.9%).공시 • Apr 16Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026.Declared Dividend • Apr 04Dividend of CHF5.00 announcedShareholders will receive a dividend of CHF5.00. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Jan 29+ 1 more updateLonza Group AG Proposes Dividend for 2025Lonza Group AG announced that Board of Directors will propose to increase the dividend for 2025 by +25% to CHF 5.00 per share at the Lonza AGM in May 2026. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserve, meaning it will be exempt from Swiss withholding tax.모든 업데이트 보기Recent updates공시 • Jun 09LONZA GROUP LTD Announces Management ChangesLONZA GROUP LTD announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza's Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations. Most recently, he served as Roche's Global Head of External Engagement. Over an 11-year career at Roche, he held a number of leadership roles in both the Pharmaceuticals Division and Group functions. Prior to joining Roche, he worked in management consulting at AON and investment banking at Rothschild. Hans holds degrees from the University of Cambridge, the London School of Economics and University of Durham.Board Change • Jun 01High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Director Steve Fry was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 05Upcoming dividend of CHF5.00 per shareEligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (0.9%).공시 • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.공시 • Apr 16Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026.Declared Dividend • Apr 04Dividend of CHF5.00 announcedShareholders will receive a dividend of CHF5.00. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 02Lonza Group AG, Annual General Meeting, May 08, 2026Lonza Group AG, Annual General Meeting, May 08, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 02Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024)Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024)Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Life Sciences industry in Europe.공시 • Jan 29+ 1 more updateLonza Group AG Proposes Dividend for 2025Lonza Group AG announced that Board of Directors will propose to increase the dividend for 2025 by +25% to CHF 5.00 per share at the Lonza AGM in May 2026. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserve, meaning it will be exempt from Swiss withholding tax.공시 • Jan 28+ 2 more updatesLonza Group AG to Report Q1, 2026 Results on May 08, 2026Lonza Group AG announced that they will report Q1, 2026 results on May 08, 2026공시 • Nov 25+ 1 more updateMicrosize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG (SWX:LONN).Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG (SWX:LONN) on November 24, 2025. Microsize and Schedio will jointly invest in Mic Mac to further enhance its capabilities and accelerate modernization. The partnership aims to establish an integrated European-American network for advanced particle engineering, combining Microsize’s CDMO expertise with Schedio’s process equipment and containment technologies. The transaction is subject to customary closing conditions and is expected to close during the first quarter of 2026.공시 • Oct 24Lonza Group Ag Affirms Earnings Guidance for 2025Lonza Group AG affirmed earnings guidance for 2025. For the period, company expects CER sales growth of 20-21%.공시 • Sep 13Lonza Group AG Announces Executive Changes, Effective October 1, 2025Lonza Group AG announced the appointment of Jason Berndt as Head of Group Operations, Executive Vice President, and member of the Executive Committee (EC), effective October 1, 2025. Jason brings over two decades of experience in global operations, having held leadership roles in operational excellence, manufacturing, supply chain management, technical services, and network transformations across leading pharmaceutical and consumer goods companies. He most recently served as Head of Global Technical Services and Senior Vice President at Bristol-Myers Squibb. Prior to this, he spent over eight years in leadership roles at Teva Pharmaceuticals, six years in manufacturing operations at Procter & Gamble, and two years as a consultant at McKinsey and Company. Jason began his career in the US Army, serving five years as a military officer. He holds a Bachelor of Science degree from the United States Military Academy at West Point and an MBA from the University of Michigan. Maria Soler Nunez, currently Head of Group Operations, has been appointed as Chief Quality Officer and Executive Vice President, remaining a member of the EC, effective October 1, 2025. Maria joined Lonza in 2022 and has successfully led Lonza’s engineering, procurement, supply chain management, operational excellence, and program management Group Functions. In her new role, she will be responsible for upholding and reinforcing the highest quality standards across Lonza’s global development and manufacturing network, as well as overseeing regulatory affairs and regulatory compliance. Maria has 28 years of experience in manufacturing and quality roles in the pharmaceutical industry, having worked in multiple countries including Spain, Switzerland, and the US. Before joining Lonza, she served as Chief Quality Officer at Novartis and worked with Eli Lilly and Company for 12 years. Commencing 1 October 2025 and continuing until his retirement in 2026, Oliver Schläfli, currently serving as Global Head of Quality, will transfer his responsibilities to Maria and provide counsel on different projects across the organization.Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF6.08 (vs CHF4.61 in 1H 2024)First half 2025 results: EPS: CHF6.08 (up from CHF4.61 in 1H 2024). Revenue: CHF3.58b (up 17% from 1H 2024). Net income: CHF426.0m (up 30% from 1H 2024). Profit margin: 12% (up from 11% in 1H 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.공시 • May 11+ 1 more updateLonza Group AG Announces Board AppointmentsLonza Group Ltd. at its AGM held on 9 May 2025, approved election of three newly proposed Board members – Juan Andres, Eric Drapé and David Meline – was approved by the shareholders, each for a term in office until the completion of the AGM 2026. Eric Drapé will join the Board on 14 May 2025, following the expiry of his current contractual commitments.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 1LONN 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: 1LONN 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Lonza Group 배당 수익률 vs 시장1LONN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1LONN)1.0%시장 하위 25% (IT)1.6%시장 상위 25% (IT)4.8%업계 평균 (Life Sciences)0.8%분석가 예측 (1LONN) (최대 3년)1.4%주목할만한 배당금: 1LONN 의 배당금( 1.02% )은 Italian 시장에서 배당금 지급자의 하위 25%( 1.61% )와 비교해 주목할 만하지 않습니다.고배당: 1LONN 의 배당금( 1.02% )은 Italian 시장에서 배당금 지급자의 상위 25%( 4.78% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 38.5% )로 1LONN 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 1LONN 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 16:20종가2026/06/11 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lonza Group AG는 50명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Charles PitmanBarclaysSebastian BrayBerenbergXian DengBerenberg47명의 분석가 더 보기
Upcoming Dividend • May 05Upcoming dividend of CHF5.00 per shareEligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (0.9%).
공시 • Apr 16Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026.
Declared Dividend • Apr 04Dividend of CHF5.00 announcedShareholders will receive a dividend of CHF5.00. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Jan 29+ 1 more updateLonza Group AG Proposes Dividend for 2025Lonza Group AG announced that Board of Directors will propose to increase the dividend for 2025 by +25% to CHF 5.00 per share at the Lonza AGM in May 2026. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserve, meaning it will be exempt from Swiss withholding tax.
공시 • Jun 09LONZA GROUP LTD Announces Management ChangesLONZA GROUP LTD announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza's Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations. Most recently, he served as Roche's Global Head of External Engagement. Over an 11-year career at Roche, he held a number of leadership roles in both the Pharmaceuticals Division and Group functions. Prior to joining Roche, he worked in management consulting at AON and investment banking at Rothschild. Hans holds degrees from the University of Cambridge, the London School of Economics and University of Durham.
Board Change • Jun 01High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Director Steve Fry was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 05Upcoming dividend of CHF5.00 per shareEligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (0.9%).
공시 • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.
공시 • Apr 16Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026.
Declared Dividend • Apr 04Dividend of CHF5.00 announcedShareholders will receive a dividend of CHF5.00. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 02Lonza Group AG, Annual General Meeting, May 08, 2026Lonza Group AG, Annual General Meeting, May 08, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 02Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024)Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.
Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024)Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Life Sciences industry in Europe.
공시 • Jan 29+ 1 more updateLonza Group AG Proposes Dividend for 2025Lonza Group AG announced that Board of Directors will propose to increase the dividend for 2025 by +25% to CHF 5.00 per share at the Lonza AGM in May 2026. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserve, meaning it will be exempt from Swiss withholding tax.
공시 • Jan 28+ 2 more updatesLonza Group AG to Report Q1, 2026 Results on May 08, 2026Lonza Group AG announced that they will report Q1, 2026 results on May 08, 2026
공시 • Nov 25+ 1 more updateMicrosize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG (SWX:LONN).Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG (SWX:LONN) on November 24, 2025. Microsize and Schedio will jointly invest in Mic Mac to further enhance its capabilities and accelerate modernization. The partnership aims to establish an integrated European-American network for advanced particle engineering, combining Microsize’s CDMO expertise with Schedio’s process equipment and containment technologies. The transaction is subject to customary closing conditions and is expected to close during the first quarter of 2026.
공시 • Oct 24Lonza Group Ag Affirms Earnings Guidance for 2025Lonza Group AG affirmed earnings guidance for 2025. For the period, company expects CER sales growth of 20-21%.
공시 • Sep 13Lonza Group AG Announces Executive Changes, Effective October 1, 2025Lonza Group AG announced the appointment of Jason Berndt as Head of Group Operations, Executive Vice President, and member of the Executive Committee (EC), effective October 1, 2025. Jason brings over two decades of experience in global operations, having held leadership roles in operational excellence, manufacturing, supply chain management, technical services, and network transformations across leading pharmaceutical and consumer goods companies. He most recently served as Head of Global Technical Services and Senior Vice President at Bristol-Myers Squibb. Prior to this, he spent over eight years in leadership roles at Teva Pharmaceuticals, six years in manufacturing operations at Procter & Gamble, and two years as a consultant at McKinsey and Company. Jason began his career in the US Army, serving five years as a military officer. He holds a Bachelor of Science degree from the United States Military Academy at West Point and an MBA from the University of Michigan. Maria Soler Nunez, currently Head of Group Operations, has been appointed as Chief Quality Officer and Executive Vice President, remaining a member of the EC, effective October 1, 2025. Maria joined Lonza in 2022 and has successfully led Lonza’s engineering, procurement, supply chain management, operational excellence, and program management Group Functions. In her new role, she will be responsible for upholding and reinforcing the highest quality standards across Lonza’s global development and manufacturing network, as well as overseeing regulatory affairs and regulatory compliance. Maria has 28 years of experience in manufacturing and quality roles in the pharmaceutical industry, having worked in multiple countries including Spain, Switzerland, and the US. Before joining Lonza, she served as Chief Quality Officer at Novartis and worked with Eli Lilly and Company for 12 years. Commencing 1 October 2025 and continuing until his retirement in 2026, Oliver Schläfli, currently serving as Global Head of Quality, will transfer his responsibilities to Maria and provide counsel on different projects across the organization.
Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF6.08 (vs CHF4.61 in 1H 2024)First half 2025 results: EPS: CHF6.08 (up from CHF4.61 in 1H 2024). Revenue: CHF3.58b (up 17% from 1H 2024). Net income: CHF426.0m (up 30% from 1H 2024). Profit margin: 12% (up from 11% in 1H 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
공시 • May 11+ 1 more updateLonza Group AG Announces Board AppointmentsLonza Group Ltd. at its AGM held on 9 May 2025, approved election of three newly proposed Board members – Juan Andres, Eric Drapé and David Meline – was approved by the shareholders, each for a term in office until the completion of the AGM 2026. Eric Drapé will join the Board on 14 May 2025, following the expiry of his current contractual commitments.